Literature DB >> 22469609

Local sclerotherapy with polydocanol (Aethoxysklerol®) for the treatment of Epistaxis in Rendu-Osler-Weber or Hereditary Hemorrhagic Telangiectasia (HHT): 15 years of experience.

Darío Morais1, Teresa Millás, Roberto Zarrabeitia, Luisa M Botella, Ana Almaraz.   

Abstract

Hereditary Haemorrhagic Telangiectasia or Rendu-Osler-Weber syndrome is a rare autosomal dominant vascular disease characterized by mucocutaneous and gastrointestinal telangiectases and localized arteriovenous malformations in lung, brain and liver. Epistaxis, due to rupture of telangiectases of the nasal mucosa, is the most frequent clinical manifestation, leading in many cases to severe impairment of the quality of life in the patients. Though several treatments have been used to reduce epistaxis, none have been completely effective, with the exception of polydocanol (Aethoxysklerol®) in submucosal or subpericondrial injections, which was first presented in 2000 with very good results. After fifteen years using polydocanol in submucosal injections on 45 patients and with nearly 300 injections, we have observed that in 95% of all cases, their nose bleeds improved with respect to frequency and quantity without any important side effects. There was just one case of septal perforation, another with increased septal perforation, and one patient who suffered from dizziness and blurred vision for a few minutes. In this paper the results obtained using this technique over a fifteen-year period will be presented and evaluated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22469609     DOI: 10.4193/Rhino11.142

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  5 in total

1.  Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia.

Authors:  Holly Boyer; Patricia Fernandes; Chap Le; Bevan Yueh
Journal:  Int Forum Allergy Rhinol       Date:  2015-02-02       Impact factor: 3.858

Review 2.  Optimal management of hereditary hemorrhagic telangiectasia.

Authors:  Neetika Garg; Monica Khunger; Arjun Gupta; Nilay Kumar
Journal:  J Blood Med       Date:  2014-10-15

3.  Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry.

Authors:  Antoni Riera-Mestre; José María Mora-Luján; Javier Trujillo-Santos; Jorge Del Toro; José Antonio Nieto; José María Pedrajas; Raquel López-Reyes; Silvia Soler; Aitor Ballaz; Pau Cerdà; Manel Monreal
Journal:  Orphanet J Rare Dis       Date:  2019-08-09       Impact factor: 4.123

4.  Endoscopic surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia: our experience.

Authors:  Fabio Pagella; Alessandro Pusateri; Eugenia Maiorano; Giuseppe Spinozzi; Sara Ugolini; Roberta Lizzio; Rosolino Mirabella; Carmine Tinelli; Carla Olivieri; Elina Matti
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-02       Impact factor: 2.124

5.  Comparison of Local Sclerotherapy With Lauromacrogol Versus Nasal Packing in the Treatment of Anterior Epistaxis.

Authors:  Paolo Farneti; Ernesto Pasquini; Vittorio Sciarretta; Giovanni Macrì; Giulia Gramellini; Antonio Pirodda
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-04-19       Impact factor: 3.372

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.